ainewsblitz.com

Breaking

Merck and Moderna's AI-guided melanoma vaccine meets Phase 3 endpoints

  • Healthcare

Merck and Moderna said their investigational personalized mRNA therapy, intismeran autogene, met both its primary endpoint and a key secondary endpoint in a Phase 3 trial when given with KEYTRUDA after surgery for high-risk melanoma. The companies described the result as the first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer treatment, and the first late-stage study to show a clinically meaningful improvement over KEYTRUDA alone in the adjuvant melanoma setting.

Continue reading

The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.

$20
Read this article
$29/month
Unlimited — all 27,559 articles, the full archive, and comprehension quizzes
Save 72%
$98/year
≈ $8.17/month
Unlimited, billed once a year